

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁

Wenzhou Kangning Hospital Co., Ltd.

溫州康寧醫院股份有限公司

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2120)

ANNUAL REPORT OF THE COMPANY FOR THE YEAR ENDED DECEMBER 31, 2015

1. INTRODUCTION

1.1 The board of directors (the **Board**) of Wenzhou Kangning Hospital Co., Ltd. (the **Company**) is pleased to announce the consolidated annual report of the Company for the year ended December 31, 2015 (the **Reporting Period**). This report is prepared in accordance with the Accounting Standards for the Reporting Period (the **ASAPs**).

1.2 The financial statements of the Company for the Reporting Period (the **Financial Statements**) are prepared in accordance with the International Financial Reporting Standards (the **IFRSs**).

2 FINANCIAL SUMMARY

2.1 Principal Financial Data and Indicators

	For the year ended December 31,			
	2015	2014	2013	2012
	RMB'000	RMB'000	RMB'000	RMB'000
Revenue	343,674	296,296	226,363	170,813
Profit before income tax	70,170	68,567	47,576	17,964
Income tax expense	(18,548)	(17,369)	(11,383)	(4,733)
Total comprehensive income	51,622	51,198	36,193	13,231
Attributable to:				
Equity holders of the Company	55,709	51,198	36,193	13,231
Non-controlling interests	(4,087)			

	As of December 31,			
	2015	2014	2013	2012
	RMB'000	RMB'000	RMB'000	RMB'000
Total assets	1,224,434	372,339	305,679	226,667
Total liabilities	262,205	111,249	96,818	202,601
Total equity	962,229	261,090	208,861	24,066
Equity attributable to:				
Equity holders of the Company	959,716	261,090	208,861	24,066
Non-controlling interests	2,513			

3 BUSINESS PREVIEW AND TOOL

3.1 Business Preview

In 2015, the Group, which has achieved the operational capabilities for hospital equipment, facilities and services, has gained a good reputation and increased operational efficiency. In 2015, the financial results of the Group were good, with a net profit of 1,760 million in 2014, 2,010 million in 2015, and high, indicating a good financial performance.

While continuing to expand the hospital business, the Group also made a strategic layout in the medical equipment, facilities and services. In 2015, the Group acquired the equity of Ya Jia Fu Hospital (燕郊輔仁中西醫結合醫院, Yanjiao Furen Hospital), the equity of Chengdu Renyi Hospital (成都仁一醫院有限公司, Chengdu Renyi Hospital), the equity of Chengdu Jihong Hospital (成都濟宏醫院有限公司, Chengdu Jihong Hospital), the equity of Beijing Yining Hospital (北京怡寧醫院有限公司, Beijing Yining Hospital), and the equity of Beijing Jinyin Hospital (北京金銀醫院有限公司, Beijing Jinyin Hospital), increasing the number of hospital beds from 150 in 2014 to 370 in 2015 and laying a solid foundation for the future.

The Group has always believed that the core of the Group's business is the medical equipment, facilities and services. In 2015, the Group's business focus was on the medical equipment, facilities and services, with a net profit of 12 million in 2014, 25 million in 2015, and 5 million in 2016. The Group's business focus was on the medical equipment, facilities and services, with a net profit of 12 million in 2014, 25 million in 2015, and 5 million in 2016. The Group's business focus was on the medical equipment, facilities and services, with a net profit of 12 million in 2014, 25 million in 2015, and 5 million in 2016.

3.2 Business Highlights

On January 22, 2016, the Group completed the acquisition of (i) Wenzhou Medical University (溫州醫科大學) and (ii) Wenzhou Medical University School of Mental Medicine (溫州醫科大學精神醫學學院); and (iii) Wenzhou Medical University Asset Management Co., Ltd. (溫州醫科大學資產經營有限公司) and Wenzhou Guoda Information Technology Co., Ltd. (溫州國大信息科技有限公司) and Wenzhou Guoda Investment Co., Ltd. (溫州國大投資有限公司).

* For identification purposes only

司) b the C a f We h, Medical U i e i A e Ma age e C a Li i ed h, gh, blic biddi g, bjec he e e i gi f ele a f al age e e (). F de ail, lea e efe he C a ' a, ce e da ed Ja, a 22, 2016. The P chia Sch l f We h, Medical U i e i w a e abli hed Ma ch 20, 2016. A f he da e f hi a, ce e, he C a ha ac, i ed a e, i i e e i We h, G da I e e C a .

O Ja, a 28, 2016, he C a e e ed i a fa e k ag ee e w i h M . HUANG Fe g a d M . HUANG Che (c llec i el, he **endo s**.) i ela i (i) he ed e abli h e f a age c a (he **a et Company**.) b the Ve d ; (ii) he ed i i f a age e a d c, l a c e ice b the Ta ge C a P, jia g H a gfe g P chia S ecial H i al* (浦江黃鋒精神專科醫院) a d Ch, 'a H a gfe g Ka g'e H i al* (淳安黃鋒康恩醫院); a d (iii) he ed ac, i i i f 26% e, i i e e a d, b e, e ca i al i ce a e i he Ta ge C a b the C a (he **P oposed ansa tion**). U he c le i f he P ed Ta aci, i i e ec ed ha he C a w ill h ld 51% e, i i e e i he Ta ge C a . F de ail, lea e efe he C a ' a, ce e da ed Ja, a 28, 2016. The Ta ge C a w a e abli hed Feb, a 5, 2016. A f he da e f hi a, ce e, he C a ha e e ed i a age e e i ela i he P ed Ta aci .

O Feb, a 22, 2016, he C a e e ed i a a e hi age e e w i h Sha ghai Ji, Jia f, E, i I e e Ma age e C ., L d. (上海金浦健服股權投資管理有限公司, **inppv jianfv**), Sha ghai Yi che g A e Ma age e Ce e L.P. (上海銀驄資產管理中心 (有限合夥)), Ch g i g I d G da ce a d E, i I e e Fr d C ., L d. (重慶產業引導股權投資基金有限責任公司), Shi a Medical I, e C ., L d. (山東新華醫療器械股份有限公司), Jia g, Shaga g G, C ., L d. (江蘇沙鋼集團有限公司) a d USUM I e e G, C ., L d. (渝商投資集團股份有限公司) i ela i (i) he e abli h e f Ch g i g Ji, Heal hca e Se ice I d ial E, i I e e Fr d L.P.* (重慶金浦醫療健康服務產業股權投資基金合夥企業 (有限合夥)) (he **Investment Fvnd**); a d (ii) he C a ' c ib, i f RMB50.0 illi f he, b c i i he I e e Fr d. O he a e da e, he C a a d Ji, Jia f, he a agi g a e f he I e e Fr d, e e ed i a a egic c e a i age e e i ela i, a g he, ce ai igh f he C a a ali i ed a e f he I e e Fr d. F de ail, lea e efe he C a ' a, ce e da ed Feb, a 23, 2016. The I e e Fr d w a e abli hed i he PRC Ma ch 22, 2016. A f he da e f hi a, ce e, ch c ib, i ha bee a de a d he C a e ec ake, ch c ib, i i 2016.

* For identification purposes only

3.3 Business Outlook

L k i g i h e f , e , h e C a w ill f l l e e a g e h e f a a b l e
g e e l i c i e i C h i a w h i c h e c , a g e h e , b l i c e a b l i h
e d i c a l f a c i l i e a d a , a d e a d , h e a l h c a e f a c i l i e w k
h , g h e i g e w e d h i a l i 2016. I i e e c e d h a L i h a i
K a g i g H i a l C . , L d . * (臨海康寧醫院有限公司) (T i n h a i a n n i n
h o s p i t a) a d W e h , Y i i g G e i a i c H i a l C . , L d . * (溫州怡寧老
年醫院有限公司) (e n h o w i n i n e i a t i o h o s p i t a , a h l l w e d
b i d i a f h e C a w h i c h w a e f e e d a h e L , i a M e d i c a l
A e a i h e e c , f h e C a d a e d N e b e 10, 2015 (h e
P o s p e c t u s .) a d w h e i c i a l b r i e i i d e e d i c a l e i c e
f h e g e i a i c , i c h d i g g e i a i c . c h i a i c . c h l g i c a l e a e w i l l
c e c e e a i i h e f i h a l f f 2016. A h e a e i e w e w i l l a l
e e d , h e e a a i f h e e i g f P i g a g K a g i g H i a l *
(平陽康寧醫院) , Q h , Y i i g H i a l * (衢州怡寧醫院) a d S h e h e
Y i i g H i a l * (深圳怡寧醫院) , a i i g f h e c e c e e a i
i h e e c d h a l f f 2016.

[illegible]

4 A A E E D C O A D A A V

4.1 Financial Review

4.1.1 Revenue

The G e e e e e e ai l h , gh he f ll_wi g_w_wa : (i)
e e , ef e ai gi w ed h i al , a d (ii) a age e fee
f a agi g heal hca e facili ie .

* *For identification purposes only*

Revenue from operating the Group's owned hospitals

Revenue from operating the Group's owned hospitals consists of fees charged for the provision of inpatient and outpatient services, including medical diagnosis and general healthcare services, pharmaceuticals and ancillary hospital services. The table below sets forth a breakdown of revenue from operating the Group's owned hospitals for the period indicated:

	For the year ended December 31,	
	2015	2014
	(RMB'000)	(RMB'000)
Treatment and general healthcare services	240,103	206,790
Pharmaceuticals	87,740	77,384
Ancillary hospital services	2,270	1,828
Total revenue	330,113	286,002
Costs	206,283	178,766
Gross profit	123,830	107,236

Revenue from the Group's owned hospitals amounted to RMB330.1 million, representing a year-on-year increase of 15.4%, accounting for 96.1% of the total revenue from the Group for the Reporting Period, due to the increase in the overall effective service capacity of the Group's owned hospitals and the average inpatient length of stay. Patients received better service from the Group's owned hospitals than at the end of the year, with the average inpatient length of stay increasing to 129,355 (2014: 119,425) and the average bed-day increasing to 689,244 (2014: 615,242). Average length of stay increased to RMB486 (2014: average length of stay RMB482), and the average length of stay per bed increased to RMB384 (2014: RMB369), and the average price for medical services charged by Cangnan Kangning Hospital Co., Ltd. (蒼南康寧醫院有限公司) and Yongjia Kangning Hospital Co., Ltd. (永嘉康寧醫院有限公司) increased from March 1, 2015 to January 1, 2015, respectively.

Revenue from treatment and general healthcare services accounted for 72.7% of revenue from operating the Group's owned hospitals (2014: 72.3%), and revenue from pharmaceuticals accounted for 26.6% of revenue from operating the Group's owned hospitals (2014: 27.1%).

Costs from the Group's owned hospitals for the Group's inpatient services, pharmaceuticals and ancillary services, and the related expenses, depreciation and amortization, and other expenses.

Costs incurred, excluding depreciation, amounted to RMB206.3 million, an increase of 15.4% which was mainly due to the increase in depreciation. The depreciation increased by 37.5% (2014: 37.5%).

Management service fee income

The Group's management service fee income is primarily derived from the management service fee income of the healthcare facilities. The attributable profit of the management service fee income is as follows:

	For the year ended	
	December 31,	
	2015	2014
	(RMB'000)	(RMB'000)
Revenue	13,561	10,294
Costs incurred	7,006	2,547
Group profit	6,555	7,747

Management service fee income of the Group amounted to RMB13.6 million, an increase of 31.7% and accounting for 3.9% of the total revenue of the Group for 2015, due to the contribution of the management fee income of the Beijing Yiyang Hospital in 2015 which amounted to RMB1.7 million (2014: nil).

Costs of the Group for management service income is primarily attributable to the depreciation of the management facilities.

Costs incurred for management service income amounted to RMB7.0 million, an increase of 175.1%, mainly due to the increase in depreciation, mainly because of the acquisition of the Ya Jia Feng Hospital. The Group incurred 19 and 9 million for depreciation of the hospital and recorded RMB93.1 million of impairment loss. RMB3.5 million was recorded for impairment loss in 2015 as compared to 48.3% (2014: 75.3%).

4.1.2 Gross Profit and Gross Profit Margin

[illegible]

4.1.3 Other Income

O he i c e f h e G , c i f g e e g a a d
i i f acc , a able. I 2015, h e i c e a , ed
RMB3.1 illi , e e e i g a ea - - ea i c ea e f 346.2%,
i a il d e g e e g a a d , b idie .

4.1.4 Selling Expenses

In 2015, the electricity generated by the Grid, at a cost of RMB2.0 billion, decreased significantly by 5.8%, accounting for 0.6% of the total electricity generation (2014: 0.7%).

4.1.5 Administrative Expenses

Ad i i a i e e e e f he G , i a il c i f be efi
a d e e e f , a age e a dad i i a i e aff, e e e
f he ~~w~~l -b il h i al i hei c e ce e f e a i ,
de ecia i , a i a i a d he .

[illegible]

4.1.6 Finance Income

In 2015, finance income increased RMB7.6 million, increasing year-on-year income of 917.8%, mainly because the credit loss provision for the initial public offering of the H K Guangdong (USD). Higher charge of HK\$ against Rebi (RMB) increased the realized charge gain of RMB9.8 million, which offset the finance expense of 1 million, resulting in a net gain of RMB4.0 million.

4.1.7 Share of Loss of Investments Accounted for Using the Equity Method

In 2015, the share of loss accounted for using the equity method was RMB6.3 million (2014: nil), which decreased by 49% compared to Beijing Yigong He Industrial, which contributed to the share of loss in 2015 and decreased by 1 million from RMB12.8 million.

4.1.8 Income Tax Expense

In 2015, income tax expense increased RMB18.5 million, increasing year-on-year income of 6.8%, mainly due to the higher provision of RMB70.2 million (2014: RMB68.6 million). The effective rate in 2015 and 2014 was 26.4% and 25.3%, respectively.

4.1.9 Net Profit

In 2015, the attributable net profit of the Company (hereinafter referred to as "Net Profit") was RMB55.7 million, increasing year-on-year income of 8.8% compared with 2014.

4.2 Financial Position

4.2.1 Inventory

As of December 31, 2015, the ending balance decreased RMB7.5 million (as of December 31, 2014: RMB7.9 million), mainly due to the decrease in the carrying amount.

4.2.2 Trade Receivables

As of December 31, 2015, the balance of trade receivables increased RMB123.1 million (as of December 31, 2014: RMB84.5 million), mainly due to: (i) the increase in revenue from the sale of medical equipment; and (ii) the increase in the balance of trade receivables from the sale of medical equipment. As of December 31, 2015, 79.5% of trade receivables from the Group were aged within 90 days.

4.2.3 Other Receivables, Deposits and Prepayments

As of December 31, 2015, the receivables, deposits and prepayments increased RMB91.0 million (as of December 31, 2014: RMB41.2 million), mainly due to: (i) the increase of RMB25.8 million in deposits from the sale of land use rights in Weihai, Yiting Geiaic Hospital; (ii) the increase of RMB13.0 million in deposits from the sale of shares in Pingyang Kangning Hospital Co., Ltd.* (平陽康寧醫院有限公司) (Pingyang Kangning Hospital Co., Ltd.*); and (iii) the increase of RMB12.0 million in deposits from the sale of shares in Pingyang Kangning Hospital Co., Ltd.*.

4.2.4 Trade Payables

As of December 31, 2015, the payable decreased RMB20.0 million (as of December 31, 2014: RMB23.8 million), of which 84.5% were aged within 90 days.

4.2.5 Accruals and Other Payables

As of December 31, 2015, accruals and other payables increased RMB166.4 million (as of December 31, 2014: RMB60.0 million), mainly due to RMB90.5 million of accruals for the sale of land use rights in Weihai, Yiting Geiaic Hospital; and the increase of RMB75.9 million in accruals for the sale of shares in Pingyang Kangning Hospital Co., Ltd.*. The increase of RMB90.5 million in accruals for the sale of land use rights in Weihai, Yiting Geiaic Hospital is due to the increase of RMB90.5 million in the balance of trade payables for the sale of land use rights in Weihai, Yiting Geiaic Hospital. The increase of RMB75.9 million in accruals for the sale of shares in Pingyang Kangning Hospital Co., Ltd.* is due to the increase of RMB75.9 million in the balance of trade payables for the sale of shares in Pingyang Kangning Hospital Co., Ltd.*.

4.2.6 Net Current Assets

As of December 31, 2015, the net current assets of the Group increased RMB664.0 million (as of December 31, 2014: RMB86.2 million), mainly due to the increase of RMB590.7 million in the balance of trade receivables, deposits and prepayments, the increase of RMB50.0 million in the balance of trade payables, and the increase of RMB23.3 million in the balance of other receivables, deposits and prepayments. The increase of RMB590.7 million in the balance of trade receivables, deposits and prepayments is due to the increase of RMB590.7 million in the balance of trade receivables, deposits and prepayments. The increase of RMB50.0 million in the balance of trade payables is due to the increase of RMB50.0 million in the balance of trade payables. The increase of RMB23.3 million in the balance of other receivables, deposits and prepayments is due to the increase of RMB23.3 million in the balance of other receivables, deposits and prepayments.

* For identification purposes only

4.3 Diversity and Capital Resources

The able bel_v of h he i f a i a e ac ed f he c lida ed
ca h fl_v a e e f he G , f he e i d i dica ed:

Year ended December 31,

	2015	2014
	RMB'000	RMB'000
Net cash/(debt) financing activities	(5,063)	33,328
Net cash/debt investing activities	(382,367)	(60,663)
Net cash/(debt) financing activities	708,785	(2,977)
Net increase/(decrease) in cash and cash equivalents	321,355	(30,312)

4.3.1 Net Cash from Operating Activities

I 2015, e ca h , fl_w f e a i g a c i i e a , ed RMB5.1 illi . We had e ca h g e e a e d f e a i g a c i i e b e f e c h a g e i_w k i g c a i a l f RMB87.0 illi , i a i l c i i g f f i b e f e a f RMB70.2 illi a d a d j , e f d e c i a i f , e , l a a d e , i e f RMB17.3 illi . C h a g e i_w k i g c a i a l e , l e d i c a h , fl_w f RMB66.4 illi , i a i l c i i g f a i c e a e f RMB58.2 illi i a d e a d h e e c e i a b l e a a e , l f : (i) i c e a e d e a e l e a i b , a b l e h e c i , e d e a i a d c a l i g , f , h e a l h c a e f a c i l i e e_w k ; a d (ii) , e a e f e a l e e e e l a i g . We h , Y i i g G e i a i c H i a l . We had f h e c a h , fl_w f RMB25.7 illi a i b , a b l e , i c e a a i d .

4.3.2 Net Cash Used in Investing Activities

I 2015, e ca h, ed i i e i g a c i i e a , ed RMB382.4 illi , i a i l d e : (i), cha e f , la a d e, i e f RMB113.6 illi , c i i g f (1) a , aid a d e aid e a e a d, g a d e We h , Ka g i g H i a l a d (2) a , aid e a e Bei j i g Yi i g H i a l, Li hai Ka g i g H i a l a d We h , Yi i g Ge i a i c H i a l i h e i g; a d (ii) a e d e i w i h i i a l e e h e e h f RMB251.3 illi .

4.3.3 Net Cash from Financing Activities

In 2015, net cash from financing activities amounted to RMB708.8 million, mainly due to: (i) net proceeds from the initial public offering of RMB590.7 million; (ii) net proceeds of RMB78.4 million from the cash flow of the disposal of the equity interest in CITIC Bank.

4.3.4 Significant Investment, Acquisition and Disposal

The Group entered into a strategic agreement with Yajia Fintech Holdings Limited ("Yajia Fintech") in March 2015 and a strategic agreement with Ail 2015. The effective term of the strategic agreement is from April 2015 to December 2034, extendable if both parties agree to extend the term. The Group's strategic investment in Yajia Fintech Holdings Limited is a scheduled financial investment of RMB2.7 million from April 1, 2015 to December 31, 2015, increasing to RMB4.0 million from January 1, 2016, and thereafter increasing by a scheduled fixed amount of 4% to 10% until the end of 2034, from which the effective term of the strategic investment is RMB14.1 million. If Yajia Fintech Holdings Limited fails to change, the Group's investment commitment will fall. Otherwise, the Group's investment commitment will be fixed (based on the amount of Yajia Fintech Holdings Limited's capital adjustment agreed by the parties to the strategic agreement) and the effective term of the strategic investment will be the term of Yajia Fintech Holdings Limited. As a result, the Group's effective obligation to Yajia Fintech Holdings Limited is a scheduled investment of the effective term of the strategic investment. The Group's effective term of the strategic investment is a scheduled investment of RMB93.1 million. The balance sheet, as initially calculated, is calculated based on the effective term of the strategic investment.

Since the declaration of the Group, the significant investment, acquisition and disposal in 2015.

4.4 Indebtedness

4.4.1 Bank Borrowings

As of December 31, 2015, the balance of bank borrowings of the Group amounted to RMB50.0 million (as of December 31, 2014: nil), all denominated in the local currency.

4.4.2 Contingent Liabilities

As of December 31, 2015, the Group had no contingent liabilities guaranteed by the Group, and had no or no special interest in the financial institutions of the Group.

4.4.3 Asset Pledge

As of December 31, 2015, the Group's assets had been pledged.

4.4.4 Contractual Obligations

The contractual obligations of the Group include financial lease agreements. As of December 31, 2015, the future aggregate financial lease agreements, denominated in the local currency, amounted to RMB209.0 million.

4.4.5 Financial Instruments

Financial instruments of the Group consist of trade receivables, accounts payable, trade payables, trade receivables, bank borrowings, and other financial instruments. The management has assessed the credit risk, liquidity risk, and market risk of the financial instruments and determined that the financial instruments do not have a significant impact on the Group's financial position.

4.4.6 Exposure to Fluctuation in Exchange Rates

The Group's debt is denominated in US dollars, and is subject to exchange rate fluctuations against the Hong Kong dollar. The Group has entered into foreign exchange contracts to hedge its exposure to fluctuations in exchange rates.

The Group has entered into derivative financial instruments to hedge its exposure to fluctuations in exchange rates. The Group has entered into foreign exchange contracts to hedge its exposure to fluctuations in exchange rates.

4.4.7 Gearing Ratio

As at December 31, 2015, the Group's gearing ratio (total debt divided by total assets) was 11.8% (2014: 11.8%).

5 FINANCIAL RESULTS

5.1 Issuance of Shares and Dividends

The Company's share capital is denominated in US dollars. The Shareholders of the Company are entitled to receive dividends in US dollars. As at December 31, 2015, the Company's share capital was HK\$693.2 million (equivalent to RMB580.7 million) and the Company's share premium was HK\$1,000 million (equivalent to RMB833.3 million). As at the end of the reporting period, the Company's share capital was HK\$693.2 million (equivalent to RMB580.7 million) and the Company's share premium was HK\$1,000 million (equivalent to RMB833.3 million).

5.2 Dividend

The final dividend for the year ended December 31, 2015 (the **Proposed Final Dividend**) was approved by the Board of Directors of the Company at the meeting held on January 14, 2016. The Proposed Final Dividend will be paid to the Shareholders of the Company on or after February 14, 2016. The Shareholders of the Company are entitled to receive dividends in US dollars. As at the end of the reporting period, the Company's share capital was HK\$693.2 million (equivalent to RMB580.7 million) and the Company's share premium was HK\$1,000 million (equivalent to RMB833.3 million).

The dividend for the year ended December 31, 2015 (the **Proposed Final Dividend**) was approved by the Board of Directors of the Company at the meeting held on January 14, 2016. The Proposed Final Dividend will be paid to the Shareholders of the Company on or after February 14, 2016. The Shareholders of the Company are entitled to receive dividends in US dollars. As at the end of the reporting period, the Company's share capital was HK\$693.2 million (equivalent to RMB580.7 million) and the Company's share premium was HK\$1,000 million (equivalent to RMB833.3 million).

If he i di id, al h lde f H Sha e a e H g K g Maca, e ide e ide f he c, ie_which had a agreed a a e f 10% f he ca h di ide d he_wi h he PRC, de he ele a a agree e, he C a h, ld_wi hh ld a d, a i di id, al i c e a behalf f he ele a Sha eh lde a a a e f 10%. Sh, ld he i di id, al h lde f H Sha e be e ide f he c, ie_which had a agreed a a e f le ha 10%_wi h he PRC, de he ele a a agree e, he C a hall_wi hh ld a d, a i di id, al i c e a behalf f he ele a Sha eh lde a a a e f 10%. I ha ca e, if he ele a i di id, al h lde f H Sha e_wi h eclai he e a a, _wi hheld d, he a lica i f 10% a a e, he C a ca a l f he ele a agreed e fe e ial a ea e ided ha he ele a Sha eh lde, b i he e ide ce e, i ed b he ice f he a agree e C, e ha e. The C a _will a i _wi h he a ef, d a fe he a al f he c e e a a h i. Sh, ld he i di id, al h lde f H Sha e be e ide f he c, ie_which had a agreed a a e f e 10% b, le ha 20%_wi h he PRC, de he a agree e, he C a hall_wi hh ld a d, a he i di id, al i c e a a he agreed ac, al a e i acc da ce_wi h he ele a a agree e. I he ca e ha he i di id, al h lde f H Sha e a e e ide f he c, ie_which had a agreed a a e f 20%_wi h PRC, _wi hich ha e e ed i a a agree e _wi h PRC, he_wi e, he C a hall_wi hh ld a d, a he i di id, al i c e a a a a e f 20%.

5.3 P w phase, a e and Redemption of Listed e w ities

Dr i g he, e i d f he Li i g Da e Dece be 31, 2015, ei he he C a a a fi, b idia ie, cha ed, ld edee ed a f he C a ' li ed ec, i ie.

5.4 Review of Annva Presw ts

The C a ' a di c i ee ha e ie_wed he G, ' a, al e, l f he fi a cial ea e ded Dece be 31, 2015 a d ha i ed ha a lica ble acc, i g a da d a d e, i e e ha e bee c l ied_wi h a d ha ade, a e di cl, e ha e bee ade b he C a.

The C a ' a di c i ee c i f_wi de e de -e ec, i e di ec f he C a, M. HUANG Zhi (he chai a f he a, di c i ee) a d M. WONG Ra d F k La, a d e -e ec, i e di ec f he C a, M. HE Xi. A g he, M. HUANG Zhi ha he a a ia e, fe i al, alifica i (a ce ified, blic acc, a acc edi ed b he Chi e e I i, e f Ce ified P blic Acc, a (中國註冊會計師協會)).

6 COOPERATIVE COMPANY OBJECT CODE

The Company shall, with all the conditions in the Cooperative General Code (the **Cooperative General Code**) and in Article 14 of the Rules Governing the Listing of Securities. The Stock Exchange of Hong Kong Limited, the Listing of the Company's Shares on December 31, 2015, and the provisions of the Company's Articles of Association, which shall apply to the Company's Listing of the Company's Shares on December 31, 2015. The Company's Articles of Association shall have the same effect as if they were part of the Company's Memorandum of Association, and the Company shall be bound by the provisions of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and the Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited. The Company shall also be bound by the provisions of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and the Securities and Futures Commission's Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited. The Company shall also be bound by the provisions of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and the Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited.

7 FINANCIAL POLICY

7.1 Scope of work of the new house Cooperatives

The figures in this section are of the Group's results for the year ended December 31, 2015 have been agreed by the Company's Board of Directors, Price Waterhouse Coopers (PwC), the auditor, in the Group's audited consolidated financial statements for the year ended December 31, 2015. The work performed by PwC in this regard did not include a separate assurance engagement in accordance with the Hong Kong Standards on Auditing, Hong Kong Standards on Related Engagements, Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and, as a result, has not been performed by PwC in this regard.

7.2 Accounting policies

The Company has adopted the consolidated financial statements for the Group, which are significant changes in accounting policies.

7.3 Financial statements

7.3.1 Consolidated Statement of Comprehensive Income

	Year ended December 31, 2015 RMB'000	2014 RMB'000
Revenue	343,674	296,296
Cost of revenue	(213,289)	(181,313)
Gross profit	130,385	114,983
Operating expenses	3,074	689
Other losses	(144)	(151)
Selling expenses	(1,970)	(2,092)
Administrative expenses	(62,520)	(45,611)
Operating profit	68,825	67,818
Financial income	11,625	749
Financial expenses	(4,002)	
Finance income – net	7,623	749
Shareholders' share of profit of subsidiaries	(6,278)	
Profit before income tax	70,170	68,567
Income tax expense	(18,548)	(17,369)
Net profit	51,622	51,198
Other comprehensive income	–	
Total comprehensive income	51,622	51,198
Attributable to:		
Equity holders of the Company	55,709	51,198
Non-controlling interests	(4,087)	
Earnings per share		
Basic and diluted (in RMB)	1.03	1.02

7.3.2 Consolidated Balance Sheets

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Assets		
Non-current assets		
Property, plant and equipment	233,200	160,799
Land use right	20,738	21,210
Intangible assets	90,581	1,229
Investment in associates	8,422	
Deferred income taxes	10,071	4,641
Derivative assets	48,324	13,904
Total non-current assets	411,336	201,783
Current assets		
Inventory	7,506	7,911
Trade receivable	123,067	84,532
Other receivable, derivative assets	42,690	27,340
Accounts payable	20,044	13,502
Prepaid expenses	251,334	
Cash and cash equivalents	368,457	37,271
Total current assets	813,098	170,556
Total assets	1,224,434	372,339
Equity		
Equity attributable to owners of the Company		
Share capital	73,040	50,000
Capital reserve	797,510	159,153
Surplus reserve	11,342	5,708
Retained earnings	77,824	46,229
	959,716	261,090
Non-controlling interest	2,513	
Total equity	962,229	261,090

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
LIABILITIES		
non-current liabilities		
Deferred government grants	14,284	14,156
Long-term payable	98,821	12,688
total non-current liabilities	113,105	26,844
Current liabilities		
Trade payable	19,976	23,829
Accrual and other payable	63,209	47,340
Contractual liabilities	11,559	13,236
Bank borrowings	50,000	
Current financial payable	4,356	
total current liabilities	149,100	84,405
total liabilities	262,205	111,249
total equity and liabilities	1,224,434	372,339

7.4 Notes to the Financial Statements

7.4.1 General Information

The Company was established as a joint stock company in the People's Republic of China, under the name of Weisheng Kangning Mental Healthcare Hospital (溫州市康寧精神康復醫院) in the PRC on February 7, 1996. The address of the Company's registered office is at Shengji Road, Hangzhou Residential District, Weisheng, Zhejiang, the PRC.

On October 15, 2014, the Company was converted into a joint stock limited liability company named Weisheng Kangning Hospital Co., Ltd. (溫州康寧醫院股份有限公司).

The Company is engaged in the healthcare industry in the PRC.

The Company had its initial public offering on the Stock Exchange of Hong Kong on November 20, 2015.

The consolidated financial statements are prepared in RMB and expressed in the PRC Renminbi, and all figures are in thousands of RMB unless otherwise indicated.

7.4.2 Basis of Preparation

The consolidated financial statements of the Group have been prepared in accordance with the IFRS. The consolidated financial statements have been prepared, under the historical cost convention.

(a) New and amended standards adopted by the Group

The following standards and amendments have been adopted by the Group from the effective date of the financial statements beginning 1 January 2015:

Amended IAS 19 'Contributions to defined benefit plans'.

Amended financial instruments IFRS 2010-2012 Cycle, IFRS 8, 'Operating Segments', IAS 16, 'Property, plant and equipment', IAS 38, 'Intangible Assets' and IAS 24, 'Related Party Disclosures'.

Amended financial instruments IFRS 2011-2013 Cycle, IFRS 3, 'Business Combinations', IFRS 13, 'Fair Value Measurement'.

Amended IAS 27 'Earnings per share of a financial instrument'.

The directors of the Company noted that the adoption of the newly adopted IFRS had no material impact on the Group's earnings, financial position.

(b) New Hong Kong Companies Ordinance (Cap. 622)

In addition, the provisions of Part 9 Accounts and Audits of the new Hong Kong Companies Ordinance (Cap. 622) came into effect during the financial year, as a result, there are changes to the accounting and disclosure practices in the consolidated financial statements.

(c) *New standards and interpretations not yet adopted*

As at the end of the reporting period, the Group has not yet adopted the new standards and interpretations of IFRS that are effective for the first time for the reporting period commencing on or after January 1, 2015 and have been applied in the accounting period ended financial year. The effects of the new standards and interpretations on the Group's financial position and performance are not yet known.

IFRS 9, 'Financial Instruments'

IFRS 15, 'Revenue from Contracts with Customers'

IFRS 16, 'Leases'

The effects of the IFRS and IFRIC interpretations have not yet been determined. The Group will be required to adopt the new standards and interpretations when they become effective.

7.4.3 Trade Receivables

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Trade receivable	130,738	89,537
Less: provision for doubtful trade receivable	(7,671)	(5,005)
Trade receivable net	<u>123,067</u>	<u>84,532</u>

The carrying amount of the Group's trade receivable as at the end of the reporting period is RMB123,067,000, which is fully collectible.

As of December 31, 2014 and 2015, the aggregate liability for the deductible_W allowance_W is:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Aggregate liability based on the billings data:		
Bill receivable	9,580	9,927
1-3 months	74,718	45,694
4-6 months	19,635	13,082
7-12 months	19,937	14,635
1-2 years	5,075	4,574
2-3 years	1,426	1,544
Over 3 years	367	81
	<u>130,738</u>	<u>89,537</u>

According to the Group's effective budget, all bill receivable allowance_W is available.

As of December 31, 2014 and 2015, the Group's deductible allowance_W and debt_W liability_W are RMB73,442,000 and RMB113,297,000, respectively. The allowance_W is related to the amount claimed for local sales, as the budget and the sales are deductible_W which are deductible for the employee's medical expense_W and the allowance_W has been deducted by the employee's medical insurance.

The management considers that the allowance_W is highly probable to be recovered in the future. The aggregate liability for the deductible allowance_W allowance_W is:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Leasehold	110,355	71,136
1-2 years	2,800	2,269
2-3 years	142	3
Over 3 years	—	34
	<u>113,297</u>	<u>73,442</u>

As of December 31, 2014 and 2015, the receivable of RMB6,168,000 and RMB7,861,000, respectively, are included. The amount of the receivable of RMB5,005,000 and RMB7,671,000 as of December 31, 2014 and 2015, respectively. The aging of the receivable is as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Less than 1 year	3,935	2,275
1-2 years	2,275	2,305
2-3 years	1,284	1,541
Over 3 years	367	47
	<u>7,861</u>	<u>6,168</u>

The amount of the Group's receivable from the sale of the receivable is as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
At January 1,	5,005	3,699
Provision of receivable	4,907	2,957
Receivable of the affiliated companies	(2,241)	(1,304)
Write-back, net	—	(347)
At December 31,	<u>7,671</u>	<u>5,005</u>

The provision of receivable included in the consolidated statement of comprehensive income. All of the receivable are expected to be collected within one year.

The amount of the receivable from the sale of the receivable is as follows. The Group does not have any receivable from the sale of the receivable.

7.4.4 Other Receivables, Deposits and Prepayments

	As of December 31, 2015 RMB'000	2014 RMB'000
Other receivable ^(a)	14,337	1,408
Debt ^(b)	17,268	16,823
Accounts payable ^(c)	12,304	
Prepaid expense	30,007	16,686
Prepaid financial expense ^(d)	13,000	
Prepaid commissioning fee	2,594	1,216
Prepaid goods purchase	2,539	1,511
Prepaid IPO expense	—	3,477
Other	43	123
Less: impairment expense for other receivable	(1,078)	
Total	91,014	41,244
Current	42,690	27,340
Non-current	48,324	13,904
Total	91,014	41,244

The carrying charges of the Government, the receivable, deposits and the other assets of the Government are valued in RMB and are included in the fair value.

(a) I declared the receivable as of December 31, 2015, as a trade receivable at a value of RMB9,210,000. Yang F. He H. is the shareholder. The receivable will be paid by the Group. Yang F. He H. is the director in charge of all the agreed business.

[illegible]

(c) The Company entered into a written agreement with Sichuan Hongji Pacific Chemical Company Limited ("Shiwan Yonji", a subsidiary of the Defendant) in March 2015 and later decided to place an order with Sichuan Hongji. The Company placed an order of RMB12,000,000 with Sichuan Hongji for the purchase of chemical raw materials. Subsequently, the agreement was cancelled and the Defendant alleged that the agreement was entered into by Sichuan Hongji, Chengdu Jihong Chemical Company Limited ("Chen du Jihong", a wholly-owned subsidiary of the Defendant).

f Sichuan Hengji) and the Company. June 29, 2015. Pursuant to the relevant agreement, the Hengji agreed to abandon the business and the debt, and be aided by Chengdu Jihong Group. On June 12, 2015, the company signed a letter of intent with Jihong Group. On June 29, 2015, the company signed a letter of intent with Jihong Group. The agreement is as follows: f Sichuan Hengji.

On July 28, 2015, Chengdu Jihong Group changed its name to Chengdu Reishi Hengji Company Limited.

(d) The Company entered into an agreement with Pinggang Mining Specialized Fund Co., Ltd. (Pinggang Mining), a private equity fund, in October 2015, to purchase the shares of Pinggang Mining. The total consideration for the shares is RMB18,000,000. As of December 31, 2015, RMB13,000,000 was paid to Pinggang Mining.

7.4.5 Accruals and Other Payables

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Accrued employee benefits	18,637	17,939
Receivable advances	3,194	3,416
Receivable	3,004	3,362
Grantee deposits received from customers and contractors ^(a)	12,688	12,688
Other payable for purchase of land and equipment	20,831	19,916
Other payable	412	641
Advances received from associates and related parties ^(b)	3,110	1,500
Long-term payable for acquisition of land and buildings	90,489	
Accrued liabilities	11,606	
Other	2,415	566
Total	166,386	60,028
Current	63,209	47,340
Current liability for long-term payable for acquisition of land and buildings and buildings	4,356	
Non-current	98,821	12,688
Total	166,386	60,028

The carrying amount of the available-for-sale financial assets is RMB. The carrying amount of the available-for-sale financial assets is RMB. The carrying amount of the available-for-sale financial assets is RMB.

- (a) The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB.
- (b) The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB. The amount of the carrying amount of the available-for-sale financial assets is RMB.

7.4.6 Revenue

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Tea and other health care products	240,103	206,790
Pharmaceuticals	87,740	77,384
Acupuncture and other health care services	2,270	1,828
Management fee	13,561	10,294
	343,674	296,296

7.4.7 Expenses by Nature

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Employee benefits	99,988	82,750
Pharmaceuticals and medical	86,483	75,419
Deceit and damage	21,706	15,067
Quota and lease fees	8,563	10,055
Quota and lease fees and franchise health care facilities	7,388	6,612
Cash fees	11,280	8,404
Utilities fees	5,820	5,381
Advertising fees	3,388	3,900
Professional fees and fees	4,907	2,610
Professional fees and fees	1,078	
Telephone fees	2,481	3,086
Printing and mailing	1,970	2,092
Dental charges	1,814	1,834
Consulting and service	345	1,147
Licensing fees	5,177	
Advertising fees		
Advertising fees	1,532	315
Non-advertising fees	—	
Other	13,859	10,344
	277,779	229,016

7.4.8 Income Tax Expense

The income tax expense of the Group for the year ended December 31, 2014 and 2015 is analyzed as follows:

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Current income tax:		
PRC corporate income tax	23,978	19,054
Deferred income tax	(5,430)	(1,685)
	<u>18,548</u>	<u>17,369</u>

The amount of the Group's provision for income tax differs from the theoretical amount, calculated at the rate applicable in the PRC, due to the following factors:

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Provision for income tax	70,170	68,567
Calculated at the rate of 25%	17,543	17,142
Excess deductible	2,507	227
Income tax rebates	(167)	
Other items	(1,335)	
	<u>18,548</u>	<u>17,369</u>

PRC corporate income tax

The income tax provision of the Group is calculated based on the income in the PRC has been calculated at the rate of 25% which is applicable for the year, based on the existing legislation, income tax and administrative regulations, and other applicable laws and regulations.

7.4.9 Earnings per Share

Basic earnings per share

The calculation of basic earnings per share is based on the attributable dividend, which is the dividend of the Company of RMB51,198,000 and RMB55,709,000 for the ended December 31, 2014 and 2015, respectively, and the weighted average number of shares outstanding for the period of each period, calculated as follows:

Weighted average number of ordinary shares

	Period ended December 31,	
	2015	2014
	No. of shares	No. of shares
Ordinary shares issued at beginning of the period	50,000,000	50,000,000
Effect of increase of shares	4,253,370	
Weighted average number of shares outstanding for the period	<u>54,253,370</u>	<u>50,000,000</u>

The Company was established on October 15, 2014. The calculation of the Shares of the Company ended December 31, 2014 is based on 50,000,000 ordinary shares, which is the number of shares outstanding at the beginning of the period. The calculation of the Shares of the Company ended December 31, 2015 is based on 54,253,370 ordinary shares.

Diluted earnings per Share

The Company did not have any potential dilutive Shares, therefore, the diluted earnings per Share are the same as the basic earnings per Share.

7.4.10 Final Dividends

On March 11, 2015, the Board declared a final dividend of RMB18,480,000 for the year ended December 31, 2014. The dividend was paid to the shareholders on June 1, 2015 and the Company paid the dividend on July 23, 2015.

On March 24, 2016, the Board declared a final dividend of RMB18,260,000 for the year ended December 31, 2015, which is calculated based on 73,040,000 issued Shares as of December 31, 2015. The dividend will be reflected in the dividend payable in the consolidated financial statements as of December 31, 2015, and will be reflected in the financial statements as of December 31, 2016.

	Year ended December 31,	
	2015	2014
	RMB'000	RMB'000
Paid final dividend of RMB0.25 (2014: RMB0.35) to the Shareholders	18,260	18,480

7.4.11 Commitments

Capital commitments

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Contracted but not provided for		
construction building	36,635	86,130
leasehold improvements	60,529	1,784
other, including decoration	10,935	794
	108,099	88,708

Operating lease commitments

The Group lease certain office buildings and industrial premises on a non-cancellable lease agreement.

The Group's future aggregate minimum lease payments under non-cancellable operating leases are as follows:

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Non-lease liability	28,593	26,654
Lease liability and		
lease liability	74,546	80,867
Lease liability	105,831	129,116
	<u> </u>	<u> </u>
	208,970	236,637
	<u> </u>	<u> </u>

Investment in subsidiaries

	As of December 31,	
	2015	2014
	RMB'000	RMB'000
Non-lease liability	43,000	8,600
Lease liability and		
lease liability	15,600	2,400
	<u> </u>	<u> </u>
	58,600	11,000
	<u> </u>	<u> </u>

7.4.12 Principal Subsidiaries

The following is a list of the principal subsidiaries of the Company as at December 31, 2015:

Company Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued share capital and debt securities	Proportion of shares directly held by parent (%)	Proportion of shares held by the company (%)	Proportion of shares held by non-controlling interests (%)
Cangnan Kangning Hospital Co., Ltd. (蒼南康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Qingdao Kangning Hospital Co., Ltd. (青島康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Yongjia Kangning Hospital Co., Ltd. (永嘉康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Yueqing Kangning Hospital Co., Ltd. (樂清康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB1,000,000	100%	100%	
Shenzhen Yining Hospital Co., Ltd. (深圳市怡寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB16,600,000		52%	48%
Weihai Kangning Judicial Forensic Center (溫州康寧司法鑒定所)	The PRC, Sole proprietorship	Forensic identification in PRC	Paid-in capital of RMB500,000	100%	100%	
Linhai Kangning Hospital Co., Ltd. (臨海康寧醫院有限公司)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB2,000,000	80%	80%	20%
Weihai Yining Geriatric Hospital Co., Ltd. (溫州怡寧老年醫院有限公司) ^(a)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB10,000,000	100%	100%	
Pingyang Kangning Hospital Co., Ltd. (平陽康寧醫院有限公司) ^(b)	The PRC, Limited liability company	Private hospital in PRC	Paid-in capital of RMB6,000,000	100%	100%	
Shenzhen Yining Medical Investment Co., Ltd. (深圳怡寧醫療投資有限公司) ^(c)	The PRC, Limited liability company	Investment holding in PRC	Nil	100%	100%	
Quzhou Yining Hospital Co., Ltd. (衢州怡寧醫院有限公司) ^(d)	The PRC, Limited liability company	Private hospital in PRC	Nil	60%	60%	40%
Hangzhou Honglan Information Technology Co., Ltd. (杭州宏瀾信息科技有限公司) ^(e)	The PRC, Limited liability company	Online medical consulting in PRC	Nil	100%	100%	
Lanfang Yining Hospital Management Co., Ltd. (廊坊市怡寧醫院管理有限公司) ^(f)	The PRC, Limited liability company	Hospital management consulting in PRC	Nil	100%	100%	

All the subsidiaries are established in the PRC and all issued liabilities are in the Renminbi. We have no significant financial commitments which are in foreign currencies.

- (a) We have no significant financial commitments, and we have no liabilities as of December 31, 2015.
- (b) Ping An Kaigong Financial Co., Ltd. has no liabilities as of December 31, 2015.
- (c) Shenzhen Yigang Medical Investment Co., Ltd. has no liabilities as of December 31, 2015.
- (d) Qihang Yigang Financial Co., Ltd. has no liabilities as of December 31, 2015.
- (e) Hangzhou Hengfa Intelligent Co., Ltd. has no liabilities as of December 31, 2015.
- (f) Laogang Yigang Financial Management Co., Ltd. has no liabilities as of December 31, 2015.

Bodong
Guoan Hospital Co., Ltd.
Chairman

Zhejiang, the PRC
 March 29, 2016

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. YANG Yang and Ms. HE Xin; and the independent non-executive directors are Mr. CHONG Yat Keung, Mr. HUANG Zhi and Mr. WONG Raymond Fook Lam.